HCW starts Humanigen at buy; PT $31

H.C. Wainwright launched coverage of Humanigen (NASDAQ:HGEN) with a “buy” rating and price target of $31. The stock closed at $12.03 on Oct. 13.

The company’s lead asset, lenzilumab, is an antibody targeting granulocyte-macrophage colony-stimulating factor, a central player in the inflammatory cascade.

“This mechanism of action is being pursued in several indications where the ongoing fire of inflammation is a major contributor to mortality and morbidity, starting with COVID-19,” writes analyst Joseph Pantginis, Ph.D.

Dr. Pantginis said he believes the shares should be attractive to a broader set of investors as commercialization is on the horizon; upcoming positive data news flow should be abundant; and development in several indications continues, which could significantly expand the overall market potential for the antibody.

Lenzilumab’s development is furthest along in treating COVID-19 patients as the underlying mechanism of action has “generated promising data in patients, to date, and is now in the league with major players,” he added.

The company’s 300-patient Phase 3 trial is expected to read out in the fourth quarter of 2020. The randomized one-to-one trial is comparing lenzilumab plus standard of care versus standard of care alone in hospitalized patients. The primary endpoint is time to recovery by day 28.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.